Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Impedimed Limited ( (AU:IPD) ) has shared an update.
Impedimed Limited has unveiled plans for a major capital raising via both a placement and a securities purchase plan, proposing to issue up to 1.62 billion new ordinary shares alongside substantial tranches of low‑exercise‑price options. The structure includes attaching options exercisable at $0.01 expiring in March 2027 and follow‑on options at $0.015 expiring in December 2027, potentially providing the company with additional future funding flexibility and significantly expanding its capital base, with implications for existing shareholder dilution and the company’s capacity to finance its strategic and operational initiatives.
The offer to retail investors under the securities purchase plan and the concurrent placement are both scheduled to settle in mid‑June 2026, after a record date of 1 May 2026 and offer close on 5 June 2026. By pursuing this dual‑track equity raising, Impedimed is positioning itself to secure substantial new capital while aligning the timing and terms of the instruments, which may enhance liquidity in its shares, support ongoing product development and commercialization efforts, and influence its longer‑term market positioning in the medtech sector.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
Impedimed Limited is an Australian medical technology company listed on the ASX that develops and markets bioimpedance-based diagnostics. Its primary products focus on fluid status and body composition assessment, with applications in clinical settings such as oncology and cardiology, targeting hospitals and specialist practices seeking objective fluid management tools.
YTD Price Performance: -58.82%
Average Trading Volume: 4,907,406
Technical Sentiment Signal: Sell
Current Market Cap: A$28.54M
See more insights into IPD stock on TipRanks’ Stock Analysis page.